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Abstract: Thymus-expressed chemokine (CCL25) is a potent cell attractant for mesenchymal stromal
cells, and therefore it is a candidate for in situ cartilage repair approaches focusing on the recruitment
of endogenous repair cells. However, the influence of CCL25 on cartilage is unknown. Accordingly,
in this study, we investigated the effect of CCL25 on tissue-engineered healthy and osteoarthritic
cartilage. Porcine chondrocytes were cultured in a three-dimensional (3D) micromass model that
has been proven to mimic key-aspects of human cartilage and osteoarthritic alterations upon
stimulation with tumor necrosis factor-α (TNF-α). Micromass cultures were stimulated with CCL25
(0, 0.05, 0.5, 5, 50, 500 nmol/L) alone or in combination with 0.6 nmol/L TNF-α for seven days.
Effects were evaluated by life/dead staining, safranin O staining, histomorphometrical analysis of
glycosaminoglycans (GAGs), collagen type II (COL2A1) real-time RT-PCR and Porcine Genome Array
analysis. 500 nmol/L CCL25 led to a significant reduction of GAGs and COL2A1 expression and
induced the expression of matrix metallopeptidases (MMP) 1, MMP3, early growth response protein 1
(EGR1), and superoxide dismutase 2 (SOD2). In concentrations lower than 500 nmol/L, CCL25 seems
to be a candidate for in situ cartilage repair therapy approaches.
Keywords: CCL25; Thymus-expressed chemokine; cartilage; in vitro osteoarthritis model; in situ
tissue engineering
1. Introduction
Regenerative cell-based therapies for osteoarthritis (OA), like autologous chondrocyte implantation,
have already reached clinical practice for the treatment of traumatic focal and early degenerative cartilage
defects [1]. Furthermore, therapy approaches that combine microfracture and cell-free implants have also
reached the clinic [2]. In such in situ tissue engineering applications, blood and bone marrow cells fill
the defect and induce, supported by implants, the formation of cartilage [3]. This strategy avoids cell
harvesting and expansion, donor site morbidity-related pain and impairment, and reduces the complexity
of surgical interventions. Next generation in situ therapy approaches focus on molecules that actively
recruit endogenous repair cells, such as mesenchymal stem- or stromal cells (MSC) [3].
MSC play a pivotal role in the development of regenerative OA therapies. They have been found in
distinct joint locations, like synovial membrane and fluid, infrapatellar fat pad, and bone marrow [4,5].
MSC differentiate into chondrocytes, secrete regenerative factors, exosomes and microparticles, and
modulate immune responses [6–8]. Different molecules, such as growth factors and chemokines, have
been identified to mediate MSC migration in vitro [9]. MSC express several chemokine receptors [10],
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and chemokines, like stromal cell-derived factor 1α (CXCL12), CCL2-4, and -7, are known to be
expressed at damaged tissue sites and mediate MSC homing, leading to microenvironment changes
and functional improvement [11–13].
In a recent study, thymus-expressed chemokine (CCL25) was pointed out to be a candidate for in
situ tissue engineering [14]. Its chemotactic effect on human bone marrow MSC was shown in Boyden
chamber assays, and expression profiling of CCL25 stimulated MSC revealed the induction of genes
coding for factors that are involved in the migration and homing of bone marrow cells [15]. CCL25 is
known to be a ligand of the C-C motif chemokine receptor 9 (CCR9) on T cells and different other cells
that are located in the small intestine [16]. It plays an important role for T cell trafficking in thymus
and small intestine [17–19]. CCL25 is also present in the synovial fluid of healthy people and patients
with OA or rheumatoid arthritis [20].
Our overall aim is to establish an in situ cartilage repair approach based on injectable hydrogel
hyaluronic acid combined with CCL25 to recruit repair cells to damaged or degenerated cartilage
sites [21]. However, the role of CCL25 in the joint cavity and its influence on cartilage remains unclear.
Therefore, in this study, we investigated the effect of recombinant human CCL25 on migration
of porcine MSC in a Boyden chamber assay, and on tissue-engineered cartilage, as depicted in the
experimental flow chart (Figure 6). For cartilage formation, porcine chondrocytes were three-dimensional
(3D)-cultured for 14 days in high-density micromass cultures to form extracellular matrix (ECM), and
stimulated for further seven days with different concentrations of CCL25 alone or in combination with
tumor necrosis factor α (TNF-α). The porcine micromass model is reproducible, well characterized, and
has been proven to mimic substantial aspects of human native cartilage and OA alterations upon TNF-α
stimulation [22]. For the first time, we observed a dose range of CCL25 without negative effects on
tissue-engineered cartilage ECM and chondrocyte viability, which is relevant to establish an in situ repair
approach with CCL25 to recruit cells to damaged or degenerated cartilage sites.
2. Results
2.1. CCL25 Induced Migration of Porcine MSC
To assess whether recombinant human CCL25 activates porcine cells, we performed a migration
assay with porcine MSC. Cells of all three donors showed a dose-dependent migratory response
(Figure 1). In the CCL25-free control group, 1964 ± 300 (mean cell number ± standard deviation SD)
out of 30,000 MSC passed the membrane. We measured significant MSC migration at 1000 nmol/L
CCL25 (5503 ± 1084 cells). Lower concentrations did not stimulate MSC migration. These results
are comparable to human MSC [15] and they demonstrate that recombinant human CCL25 shows
functional activity on porcine cells.
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Figure 1. Mesenchymal stem- or stromal cells (MSC) migration assay. 96-well format chemotaxis
assays were performed to investigate the dose-dependent migratory effect of recombinant human
thymus-expressed chemokine (CCL25) on porcine MSC (n = 3 donors, all measured in triplicates).
Recombinant human CCL25 induces the migration of porcine MSC. The results demonstrate a biological
effect of human CCL25 on pig cells comparable to human cells [15]. Data are expressed as mean numbers
of migrated MSC ± standard deviation (SD). * indicates p < 0.05 compared with 0 nmol/L CCL25 control.
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2.2. Effect of CCL25 on Chondrocyte Viability
Next, we stimulated untreated and TNF-α treated porcine chondrocytes in 3D high-density
micromasses with different CCL25 concentrations for seven days (Figure 2). Live/dead staining
revealed a high cell viability of 98–100% even at the highest concentration of 500 nmol/L CCL25
(Figure 2A,C) and regardless of the combination with TNF-α (Figure 2B,C). All in all, no significant or
dose-dependent stimulation of cell death was observed.
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Figure 2. Life/dead assay. (A) Micromass after treatment with 500 nmol/L CCL25, most chondrocytes 
were viable (green, fluorescein diacetate stained), only a few were dead (red, propidium iodide 
stained). (B) Combination of 500 nmol/L CCL25 with 0.6 nmol/L tumor necrosis factor α (TNF-α) did 
not result in significant increased number of dead chondrocytes. (magnification of all images ×40) (C) 
Micromasses of each donor group (n = 4 donor groups) stimulated with CCL25 (0, 0.05, 0.5, 5, 50, 500 
nmol/L) without (black) or with 0.6 nmol/L TNF-α (white) for seven days. The diagram shows the 
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Safranin O staining of tissue-engineered, not TNF-α treated micromasses revealed a negligible 
effect of CCL25 on GAG-content up to a concentration of 5-50 nmol/L (Figure 3A). At higher 
concentrations, GAG-content was decreased. This was confirmed by semi-quantitative 
histomorphometry (Figure 3B). The mean intensity and SD of unstimulated controls was 101.0 ± 64.1. 
ANOVA indicated significant differences between groups, post hoc analysis demonstrated no 
significant differences between controls and cultures stimulated with 0.05, 0.5, 5, and 50 nmol/L CCL25. 
At 500 nmol/L mean intensities significantly decreased to 45.1 ± 18.0. Therefore, a dose-dependent effect 
on GAG-content was observed. In presence of TNF-α, safranin O staining indicated a decreased GAG-
content at 500 nmol/L CCL25 (Figure 3A). Histomorphometry confirmed a significant decrease in mean 
intensity from 69.7 ± 27.0 at 0 to 29.9 ± 18.1 at 500 nmol/L CCL25 (Figure 3B). Independent of the CCL25 
concentration, GAG-content was significantly lower in TNF-α treated as compared to untreated 
micromasses (Figure 3B). 
Figure 2. Life/dead assay. (A) Micromass after treatment with 500 nmol/L CCL25, most chondrocytes
were viable (green, fluorescein diacetate stained), only a few were dead (red, propidium iodide
stained). (B) Combination of 500 nmol/L CCL25 with 0.6 nmol/L tumor necrosis factor α (TNF-α) did
not result in significant increased number of dead chondrocytes. (magnification of all images ×40)
(C) Micromasses of each donor group (n = 4 donor groups) stimulated with CCL25 (0, 0.05, 0.5, 5, 50,
500 nmol/L) without (black) or with 0.6 nmol/L TNF-α (white) for seven days. The diagram shows the
mean numbers of viable chondrocytes ± SD. CCL25 has no significant effect on chondrocyte viability.
2.3. CCL25-dose Dependent Reduction of GAGs
Safranin O staining of tissue-engineered, not TNF-α treated micromasses revealed a negligible effect
of CCL25 on GAG-content up to a concentration of 5-50 nmol/L (Figure 3A). At higher concentrations,
GAG-content was decreased. This was confirmed by semi-quantitative histomorphometry (Figure 3B).
The mean intensity and SD of unstimulated controls was 101.0 ± 64.1. ANOVA indicated significant
differences between groups, post hoc analysis demonstrated no significant differences between controls
and cultures stimulated with 0.05, 0.5, 5, and 50 nmol/L CCL25. At 500 nmol/L mean intensities
significantly decreased to 45.1± 18.0. Therefore, a dose-dependent effect on GAG-content was observed.
In presence of TNF-α, safranin O staining indicated a decreased GAG-content at 500 nmol/L CCL25
(Figure 3A). Histomorphometry confirmed a significant decrease in mean intensity from 69.7± 27.0 at 0
to 29.9± 18.1 at 500 nmol/L CCL25 (Figure 3B). Independent of the CCL25 concentration, GAG-content
was significantly lower in TNF-α treated as compared to untreated micromasses (Figure 3B).
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days of CCL25 treatment without or with 0.6 nmol/L TNF-α supplementation. Data are expressed as 
mean expression values in percent GAPDH ± SD. * indicates p < 0.05 for micromasses induced with 
CCL25 as compared with 0 nmol/L control. # indicates p < 0.05 for micromasses induced with CCL25 
compared with micromasses induced with CCL25 and TNF-α. 
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CCL25 (Figure 3C). Up to 50 nmol/L CCL25, the COL2A1 expression levels were significantly lower 
in TNF-α treated as compared to untreated micromasses (Figure 3C). 
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21 (Supplementary Table 1). Marker genes known in context of differentiation and hypertrophy were 
not detected or low expressed (COL1A1). COL10A1 was present on day 14 but not 21. Expression of 
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were down-regulated at day 21. All of these data implied appropriate quality of tissue-engineered 
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Figure 3. Histomorphometrical analysis and real-time RT-PCR. (A) Safranin O staining of representative
stained slices to visualize the negative correlation between cartilage glycosaminoglycan content and
CCL25 concentration in porcine micromass cultures with and without TNF-α (magnification ×40).
(B) Semi-quantitative histomorphometric analysis of safranin O stained micromasses of all four donor
groups after seven days of CCL25 treatment without or with 0.6 nmol/L TNF-α. Data are expressed
as mean intensities ± SD. (C) Semi-quantitative RT-PCR of micromasses of all four donor groups
after seven days of CCL25 treatment without or with 0.6 nmol/L TNF-α supplementation. Data are
expressed as mean expression values in percent GAPDH ± SD. * indicates p < 0.05 for micromasses
induced with CCL25 as compared with 0 nmol/L control. # indicates p < 0.05 for micromasses induced
with CCL25 compared with micromasses induced with CCL25 and TNF-α.
2.4. CCL25-Dependent COL2A1 Expression
The decrease in GAG-content in micromass cultures without TNF-α runs parallel to reduced
COL2A1 expression. Real-time RT-PCR revealed that COL2A1 levels of CCL25-free controls (9.6 ± 2.8%
expression of housekeeping gene GAPDH) remained approximately stable up to a concentration of
5 nmol/L CCL25 (Figure 3C). Subsequently, expression decreased slightly at 50 and significantly
(4.4 ± 2.7% GAPDH) at 500 nmol/L CCL25. Stimulation with TNF-α resulted in a low COL2A1
expression of 1.3 ± 1.2% GAPDH in control cultures, and no significant changes up to 500 nmol/L
CCL25 (Figure 3C). Up to 50 nmol/L CCL25, the COL2A1 expression levels were significantly lower in
TNF-α treated as compared to untreated micromasses (Figure 3C).
2.5. Gene Expression Profiling of Untreated and TNF-α Treated Micromasses
To analyze the changes n gen expression level in more detail, gene expression profiling with
Porcine Genome Arrays was conducted (Figure 4). After applying our selection criteria, the expression
of 787 probe-sets was significantly changed. Excluding non-assignable probe-set IDs and double
entries, 517 genes were differentially expressed; unraveling the culture effect (Figure 4A). At first, the
quality of tissue-engineered cartilage (non-stimulated micromasses at day 14 and 21) that we evaluated
based on cartilage markers reviewed by J. Martel-Pelletier (Supplementary Table S1) [23]. Genes coding
for cartilage collagens (COL2A1, -6A1, -6A3, -9A1, -9A2, -11A1) and proteoglycans (aggrecan; ACAN,
biglycan; BGN, decorin; DCN, fibromodulin; FMOD, link protein; HAPLN1, lumican; LUM; versican; VCAN)
were detected. None of them was differentially expressed between day 14 and 21 (Supplementary
Table S1). Marker genes known in context of differentiation and hypertrophy were not detected or low
expressed (COL1A1). COL10A1 was present on day 14 but not 21. Expression of catabolic factor genes,
like matrix metallopeptidases (MMP1-3, -13, -14) was measured; MMP3 and -13 were down-regulated at
day 21. All of these data implied appropriate quality of tissue-engineered cartilage for CCL25 testing.
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Next, day 14 micromasses were stimulated with TNF-α for seven days were analyzed. When
comparing with unstimulated day 21 micromasses, 285 genes, including 15 cartilage genes, were
differentially expressed (Figure 4A). Expression of ECM genes (ACAN, chondroitin sulfate proteoglycan
4; CSPG4, COL1A1, -2A1, -9A1, -A2, -11A1, cartilage oligomeric matrix protein; COMP, HAPLN1) was
down-, and of catabolism (jun B proto-oncogene; JUNB, MMP1, -3, -13) and inflammation related genes
(interleukin 18; IL18, prostaglandin E synthase; PTGES) was up-regulated. These data show relevance of
the porcine model to simulate OA-like alterations and are in line with safranin O staining and PCR
results (Figure 3A–C).
2.6. Comparative Expression Profiling of CCL25 Treated Micromasses
To study the effects of CCL25 on tissue-engineered cartilage, micromasses stimulated for
seven days with 5 and 500 nmol/L CCL25 were compared with non-stimulated (0 nmol/L CCL25)
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micromasses. We found 68 differentially expressed genes in the 5 and 269 in the 500 nmol/L group
(Figure 4A). No cartilage marker gene was significantly up-or down-regulated in the 5 nmol/L and
seven in the 500 nmol/L group (Supplementary Tables S1 and S2). Expression of transcription factor
JUNB, MMP1, and -13 were up-, and of COL1A1, -2A1, -6A1, and COMP down-regulated. Decreased
COL2A1 expression was also seen in RT-PCR (Figure 3C), and the increased expression of MMP1, and
-13 was consistent with the decreased GAG-content in micromasses treated with 500 nmol/L CCL25
(Figure 3A,B).
In the 5 nmol/L group, hyaluronan mediated motility receptor (HMMR), cell cycle regulator
cyclin A2 (CCNA2) and actin-bundling protein coding espin (ESPN) were most down-regulated
(Supplementary Table S2). Involucrin (IVL), solute carrier family 12 member 1 (SLC12A1), and
tight-junction component MARVEL domain-containing protein 3 (MARVELD3), so far all not discussed
in the context of cartilage or CCL25, were most up-regulated. Stimulation with 500 nmol/L CCL25
resulted in a four-fold higher number of differentially expressed genes (Supplementary Table S2).
We found increased expression levels of early growth response protein 1 (EGR1) and superoxide
dismutase 2 (SOD2); both being capable to suppress COL2A1 expression. Calsequestrin 2 (CASQ2)
and sphingomyelin phosphodiesterase 1 (SMPD1) were most down-, whereas tetratricopeptide repeat
domain 28 (TTC28), ankyrin family member ankyrin 3 (ANK3), and CXCL2 were most up-regulated.
Among these genes, CXCL2 was already discussed in the context of cartilage.
2.7. GeneChip Analysis of CCL25 Treated TNF-α Stimulated Micromasses
TNF-α micromasses treated for seven days with 5 and 500 nmol/L CCL25 were compared
with non-stimulated micromasses. 59 genes were differentially expressed in the 5 and 26 in the 500
nmol/L CCL25 group (Figure 4A). With fibronectin (FN1), one cartilage marker gene was significantly
regulated (down) in the 5 nmol/L group, whereas no marker gene was differentially expressed in
the 500 nmol/L group (Supplementary Tables S1 and S3). This was consistent with mean safranin
O intensities and RT-PCR values (Figure 3B,C). In the 5 nmol/L group, glutamate decarboxylase 2
(GAD2) and interleukin-8 (IL8) were most down- and FosB proto-oncogene, AP-1 transcription factor
subunit (FOSB) most up-regulated. IL8 was also strong down-regulated in the 500 nmol/L group
(Supplementary Table S3). The expression of BSCL2 coding multi-pass transmembrane protein seipin
was most down-regulated. To sum up, treatment with 5 or 500 nmol/L CCL25 resulted in a very
low number of significantly regulated genes, indicating a strong TNF-α effect in addition to the
CCL25 effect.
2.8. Hierarchical Clustering and Functional Classification of Significantly Regulated Genes
Hierarchical clustering of cartilage marker genes (Supplementary Table S1) revealed three main
groups (Figure 4B). The first group encompassed untreated and low dose treated (5 nmol/L CCL25)
chondrocyte micromasses, the second group high dose treated (500 nmol/L CCL25) micromasses, and
the third group all TNF-α stimulated micromasses; no matter if CCL25 treated or not. Furthermore,
clustering of 1044 genes differentially expressed in at least one of the six group comparisons resulted
in two main groups with two subgroups, respectively (Figure 4C). Interestingly, untreated day 21
micromasses clustered with TNF-α and 5 nmol/L CCL25 treated micromasses. We made the same
observation when clustering all 14,785 genes with known gene symbol (Figure 4D); maybe indicating
an inhibitory effect of low CCL25 doses on TNF-α signaling.
Because of the strong TNF-α effect, subsequent Gene ontology (GO) terms analysis and Kyoto
Encyclopedia of Genes and Genomes database (KEGG) pathway analysis was exclusively performed
for unstimulated micromasses. Analysis of genes that were differentially expressed after treatment
with 5 nmol/L CCL25 revealed that the most highly enriched GO terms included protein translation,
ECM breakdown, and cellular response to nitric oxide (Figure 5A). 500 nmol/L CCL25 led to a higher
number of 33 significantly enriched GO terms (Figure 5B). Considering terms matching with five or
more genes, several of these genes are involved in collagen catabolic processes, cartilage development
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and ECM organization. KEGG pathway analysis revealed no significantly enriched relevant pathway
in the 5 nmol/L group (Figure 5C). With 20 differentially expressed genes, the PI3K-Akt signaling
pathway was the dominant pathway that was influenced by 500 nmol/L CCL25 (Figure 5D). Genes of
this pathway overlap with two other significantly enriched networks: focal adhesion pathway and
ECM-receptor pathway.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  7 of 16 
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3. Discussion
In this study, we investigated dose-dependent effects of CCL25 on porcine MSC migration, and
on healthy and OA-like cartilage formed by porcine chondrocytes. So far, being only known for human
MSC [15], we report a comparable chemotactic effect of CCL25 on porcine MSC in vitro. This finding is
of highly relevance for future in vitro and in vivo model development within the scope of in situ tissue
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engineering. Furthermore, for the first time, we report effects of CCL25 on chondrocyte viability and
cartilage. CCL25 in five different concentrations alone (0.05, 0.5, 5, 50, 500 nmol/L) or in combination
with TNF-α to simulate key-aspects of OA were tested for seven days on 14 days old high-density
chondrocyte micromass cultures [22], which did not result in a significant stimulation of cell death.
In contrast, semi-quantitative histomorphometric analysis revealed a significant dose-dependent
reduction of GAG-content and RT-PCR of COL2A1 expression at 500 nmol/L CL25. For lower doses,
we measured stable GAG-content and COL2A1 expression. When TNF-α was added, the graduation
of results was limited due to its overlapping effects.
To further examine the underlying reasons for ECM alterations that were seen when tissue-engineered
cartilage was induced with high CCL25 concentrations, we compared the gene expression profiles of
micromasses induced with 5 and 500 nmol/L CCL25. We found that the expression of EGR1, coding
for a nuclear transcription factor, was 1.87-fold increased upon stimulation with 500 nmol/L CCL25.
Up-regulated expression of EGR1 was able to suppress COL2A1 transcription in chondrocytes [24,25].
We also found that SOD2 expression was 2.64-fold increased after treatment with 500 nmol/L CCL25.
SOD2 is located in mitochondria and catalyzes superoxide, one of the main reactive oxygen species
(ROS) produced by chondrocytes, into hydrogen peroxide [26]. Several proinflammatory cytokines,
such as IL-1, -4, and -6, and TNF-α were pointed out to induce SOD2 expression [26,27]. Therefore,
CCL25 seems to be another SOD2 inducing cytokine. ROS are known to take part in intracellular
signaling pathways and transcription factor regulation [28]. One of the redox-sensitive transcription
factors is EGR1 [29,30]. A previous study observed that higher hydrogen peroxide levels led to an
induced EGR1 transcription [31]. Furthermore, we observed that the expression of MMP1 and MMP13
was elevated 2.00-fold. Studies postulated that MMP1 expression is SOD2 dependent and it can
be reversed by catalase co-expression [32–34]. In addition, SOD2 overexpression enhances MMP1
promoter activity through pathways, including transcription factors like ETS proto-oncogene 1 (ETS1),
jun proto-oncogene, AP-1 transcription factor unit (JUN), and mitogen-activated protein kinases
(MAPK1, -3, -8) [26,32]. The MMP1 and MMP13 promotors both contain JUN binding sites [35,36].
Micromass cultures stimulated with 500 nmol/L CCL25 up-regulated periostin (POSTN)
expression. This secreted extracellular protein interacts with MSC during tissue repair and takes
part in collagen cross-linking [37]. POSTN expression is transcriptionally regulated by mechanical
stress, growth factors, hormones and cytokines, and it is up-regulated in OA cartilage [38,39]. Previous
studies observed that periostin induces MMP13 secretion in a dose- and time-dependent manner and
down-regulates COL2A1 expression [40]. We also found a 2.46-fold increase of janus kinase 2 (JAK2).
JAK2 is associated with cytokine receptor signaling pathways, and JAK2 inhibition can reduce MMP13
induction in chondrocytes [41,42]. Both MMP1 and MMP13 are capable of cleaving collagen type II
and are key-players in OA and RA. Taken together, we assume that high concentrations of CCL25
lead to ECM breakdown via superoxide dismutase and periostin induced MMP expression in our
micromass model.
We also detected leprecan-like 4 (LEPREL4), a gene involved in collagen biosynthesis, to be
down-regulated at 500 nmol/L CCL25 (-1.62-fold) [43]. COL10A1 is described as a marker for
chondrocyte hypertrophy that is increased in cartilage during later OA stages [44,45]. The expression
level also correlates with cartilage mineralization [46]. This cartilage marker was not significantly
up- or downregulated in any of the compared treatment groups. Moreover, the expression of CXCL2
was 4.59-fold increased in 500 nmol/L CCL25 treated micromasses. It is known that proinflammatory
cytokines, like IL-1β and TNF-α, induce CXCL2 expression in chondrocytes and that CXCL2 is
up-regulated in OA cartilage [47,48]. Expression of COL2A1 during cartilage development and OA is
controversially discussed; both up- and down regulation is reported during early and late OA [22].
However, TNF-α inhibits COL2A1 expression via transcription factor SOX9 [49], and the expression of
COL2A1 was low in all TNF-α treated micromasses. Interestingly, in contrast to untreated micromasses,
cultures that were stimulated with TNF-α and 500 nmol/L CCL25 showed no further significant
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down-regulation of COL2A1 in PCR or porcine microarrays. These finding may indicate a cartilage
protective effect in OA-like conditions.
Currently, there are limited data available on physiological CCL25 concentrations in serum
(range 0.38–5.19 nmol/L) and synovial fluid [50]. In line, one limitation of our study is the unknown
CCL25 concentration of FBS. However, micromasses with 0 nmol/L CCL25 but FBS showed no
CCL25 effects. Another limitation is that the most effective in vivo CCL25 concentration is unknown.
Therefore, a broad range of physiological and supra-physiological concentrations were tested. As seen
for other cytokines and growth- and differentiation factors, tested in vitro concentrations are often
significantly higher than concentrations found in vivo [51,52]. In this first study with five different
CCL25 concentrations combined with or without TNF-α, we focused on cell viability, ECM alterations,
and gene expression changes. The duration of cell stimulation with CCL25 should be extended in
future experiments for certain concentrations. Another limitation is that the effect of CCL25 on porcine
MSC, for example, the induction of differentiation and dedifferentiation, is not further investigated
in this study. There is some information dealing with CCR9 and human MSC differentiation in
literature [53]. Here, we aimed to focus on the effects of CCL25 on cartilage ECM and resident
chondrocytes. An additional drawback is that the dominant effect of TNF-α on tissue-engineered
cartilage may superimpose the effect of CCL25 in our study, but we could detect effects when cells
were stimulated under normal conditions with CCL25 alone. Another limitation next to the relatively
short time of stimulation with CCL25 is the small sample size. However, the aim of this study was
to cover a wide range of doses (0–1000 nmol/L CL25) under normal and osteoarthritic conditions in
order to identify potential CCL25 associated implications.
4. Materials and Methods
4.1. MSC and Chondrocyte Isolation
Tissues samples of 15 sacrificed 6–8 months old female pigs (100–125 kg) were obtained from a
slaughterhouse. Therefore, no study approval was necessary. Shortly after the pigs were slaughtered,
the whole knee joints consisting of femur, meniscus, tibia, and ligaments were packed to protect
them from drying out and stored in a cooling box at 4 to 8 ◦C. They were directly transported to
the laboratory. MSC were isolated from femoral bone marrow (n = 3 pigs) [54]. Briefly, marrow
was diluted in HANK’s solution (Merck, Darmstadt, Germany) and fat was removed. Subsequently,
cells were singularized and the suspension was centrifuged at 300× g for 6 min and resuspended in
DME-medium (Merck) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific,
Dreieich, Germany), 2 ng/mL basic fibroblast growth factor (PeproTech, Hamburg, Germany), 4 mM
L-alanyl-glutamine (Merck), 100 U/mL penicillin (Merck), and 100 µg/mL streptomycin (Merck). MSC
were plated at a density of 3 × 106/cm2, and medium was changed after 72 h. At 90% confluence,
MSC were detached with 0.05% trypsin/EDTA and subcultured up to passage 3.
Chondrocytes were isolated from femoral condyles (n = 12 pigs). Cell isolation was performed
as published previously [22]. Briefly, cartilage slices (2–3 mm) were incubated for 19 h at 37 ◦C
in spinner flasks, including an enzymatic solution of RPMI medium (Merck), 10% FBS, 100 U/mL
penicillin, 100 µg/mL streptomycin, 333.3 U/mL collagenase II (Merck), 1 U/mL collagenase P (Roche,
Mannheim, Germany,) and 33.3 U/mL hyaluronidase (Sigma-Aldrich, Steinheim, Germany). Cells
were centrifuged at 400 g for 15 min, resuspended in complete RPMI medium (RPMI with 10% FBS,
100 U/mL penicillin, 100 µg/mL streptomycin, and 170 µM L-ascorbicacid-2-phosphate), and used to
generate high-density micromasses. We depicted the entire experiment in Figure 6.
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Figure 6. Flow chart of experimental design. MSC from three donors were isolated and subcultured
up to passage three before a migration assay was performed with CCL25 (0, 0.1, 1, 10, 100, 250, 500,
1000 nmol/L). Primary chondrocytes from 12 donors were isolated from femoral condyles and pooled
equally for micromass cultures (n = 4 donor groups). After 14 days, micromasses were stimulated with
CCL25 (0, 0.05, 0.5, 5, 50, or 500 nmol/L) with or without (w/o) TNF-α. After seven days of stimulation
with CCL25 alone or in combination with TNF-α, two pictures per micromass were analyzed for
live/dead assay, six slices per micromass were stained with safranin O for histological analysis, and
four micromasses were mechanically homogenized for RNA isolation and analyzed with RT-PCR.
Afterwards, RNA from all four donor groups was pooled equally (pool 1,2,3,4) and analyzed with a
Porcine Genome Array. The microarray was performed for seven concentrations: micromasses before
treatment at day 14, icromasses after seven days of stimulation with 0, 5, 500 nmol/L CCL25 and for
micromasses after seven days of stimulation with 0, 5, 500 nmol/L CCL25, and 0.6 nmol/L TNF-α.
4.2. MSC Migration Assay
The migratory effect of recombinant human CCL25 (Order No 300-45; PeproTech) on porcine MSC
(n = 3 donors) was assessed using 96-well ChemoTx plates with 8 µm pore-size membranes (Neuro
Probe, Gaithersburg, MD, USA) [15]. Lower wells contained 40 µL deprivation medium (DMEM,
0.1% FBS) plus different CCL25 concentrations (0, 0.1, 1, 10, 100, 250, 500, 1000 nmol/L). Deprivation
medium with 10% FBS served as the positive control. Upper wells were supplied with 3 × 104 MSC
per 37.5 µL deprivation medium and incubated for 20 h. Migration assay was performed in triplicates.
Migrated cells were fixed with methanol and stained using the Hemacolor Rapid Staining Kit (Merck).
Photographs were taken and cell amount per field was enumerated with the Cell Counter plugin of
ImageJ software (NIH, Bethesda, MD, USA). Statistical analysis was performed with SigmaStat 3.5
(Systat Software, Erkrath, Germany). Normal distribution of data was checked and one-way analysis
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of variance (ANOVA) for correlated samples was used with post hoc analysis according to Fishers
Least Significant Difference-Test.
4.3. Preparation of High-Density Micromass Cultures
To generate tissue-engineered cartilage, chondrocytes were cultivated as 3D high-density
micromasses in 96-well plates (Becton Dickinson, Heidelberg, Germany). Each well was filled with
6 × 105 chondrocytes pooled from three out of 12 donors (n = 4 donor groups) per 200 µL complete
RPMI medium. To achieve ECM build-up, cells were cultivated for 14 days. For the next seven
days, medium that was supplemented with 0, 0.05, 0.5, 5, 50, or 500 nmol/L CCL25 was added and
changed every 24 h. To simulate OA-like changes, CCL25 treatment was combined with the addition
of 0.6 nmol/L TNF-α (R&D Systems, Wiesbaden, Germany) [22]. Micromasses of all four donor groups
were used to investigate the effect of 0–500 nmol/L CCL25 on normal (without TNF-α) or OA-like
chondrocytes (with TNF-α).
4.4. Live/Dead Assay
Chondrocyte micromass cultures (n = 4 donor groups) were detached, washed with Phosphate
Buffered Saline (Merck), and stained with 0.1 mg/mL propidium iodide for 2 min and 3 µg/mL
fluorescein diacetate (both Sigma-Aldrich) for 15 min. Live/dead assay was performed for one
micromass per preparation. Two fluorescence pictures were taken and the amount of vital (green) and
dead (red) cells was quantified applying the Cell Counter plugin of ImageJ on the green or red color
channel, respectively. Statistical analysis was performed with SigmaStat 3.5. ANOVA on ranks, with a
subsequent Student-Newman-Keuls-Test was conducted for data of the live/dead assay.
4.5. Histological Analysis of GAGs
Chondrocyte micromass cultures (n = 4 donor groups) were embedded in Tissue-Tek (Sakura
Finetek, Staufen, Germany), snap-frozen in liquid nitrogen, and then cut into 8 µm slices. To display
the amounts of GAGs, 0.7% safranin O (Sigma-Aldrich) in 66% ethanolic solution was used, and nuclei
were counterstained with 0.2% Fast Green FCF (Sigma-Aldrich). Semi-quantitative histomorphometric
analysis to assess the intensity of safranin O staining was performed, as previously published [22]. Briefly,
pictures were taken and all pixels in areas of interest were valued in the red-green-blue color mode with a
tool based on Xcode (Apple, Sunnyvale, CA, USA). Analysis was done in sextuplicates (n = 6 slices per
preparation). Statistical analysis was performed, as described for the MSC migration assay.
4.6. RNA Isolation and Real-Time RT-PCR
For RNA-isolation chondrocyte micromasses of each experiment (n = 4 donor groups) were
mechanically homogenized in 1 mL TRI-Reagent (Sigma-Aldrich). 133 µL 1-bromo-3-chloro-propane
(Sigma-Aldrich) were added and the solution was centrifuged for 45 min at 13,000× g. Subsequently,
the upper phase was dissolved in an equal volume of 70% ethanol and filled into a spin column. Further
steps were performed as described in the RNeasy Mini Kit protocol (Qiagen, Hilden, Germany). Purity
and concentration of RNA was tested using the NanoDrop 1000 spectrophotometer (Thermo Fisher
Scientific). RNA 6000 Nano Kit (Agilent Technologies, Santa Clara, CA, USA) was used to test
RNA integrity.
For real-time RT-PCR, RNA from chondrocyte micromasses (n = 4 donor groups) was reverse
transcribed with the iScript cDNA Synthesis Kit (BioRad, Munich, Germany). PCR was performed in
triplicates (n = 3 wells per preparation) in 96-well plates on the StepOnePlus RT-PCR System (Applied
Biosystems, Darmstadt, Germany) using TaqMan probes and primer sets (order no. in parentheses)
for glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Ss03375435_u1) and collagen type II (COL2A1,
Ss03373344_g1). GAPDH expression was used to normalize the samples, and COL2A1 expression is
given as a percentage related to GAPDH expression. Statistical analysis was performed as described
for the MSC migration assay.
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4.7. Microarray Analysis
RNA of chondrocyte micromass cultures from each of the four donor groups was pooled equally to
reduce sample size and used for expression profiling of non-stimulated micromasses at day 14, micromasses
treated with 0, 5, or 500 nmol/L CCL25 for seven days (day 14 + 7), and micromasses treated with 0, 5, or
500 nmol/L CCL25 and stimulated with 0.6 nmol/L TNF-α for seven days (day 14 + 7). Analysis
was performed with the Porcine Genome Array (Affymetrix, Freiburg, Germany) that contains
23,937 probe-sets representing 20,201 genes.
RNA processing and hybridization were performed in accordance to the manufacturer’s protocol.
We used the Affymetrix GeneChip Scanner 3000 supported by GeneChip Operating software 1.4
(GCOS) for readout [55]. Raw data were processed with GCOS and have been deposited in the
ArrayExpress database at the European Bioinformatics Institute (EMBL-EBI) under accession number
E-MTAB-7430. Briefly, they were normalized and the comparison of all seven GeneChips was
performed based on signal, detection, change and fold change (FC) values. Probe-sets that were
detected as present, significantly differentially expressed between two groups and FC ≥ 1.5 or
FC ≤ −1.5 were further analyzed. Hierarchical clustering was performed with log2-transformed
signals normalized by genes and Pearson correlation as distance measure using Genesis 1.8.1
software [56]. Furthermore, genes that were differentially expressed after CCL25 stimulation were
imported into DAVID Bioinformatics Resources. Functional annotation charts were generated applying
the categories GOTERM_BP_DIRECT (Gene Ontology-Biological Process, GO Consortium) and
KEGG_PATHWAY (Kyoto Encyclopedia of Genes and Genomes database) [57,58]. Significance of
gene-term enrichment values (EASE score) was estimated using a modified Fisher’s exact test included
in DAVID Bioinformatics Resources. P-values < 0.05 were considered to be significant. To match
names for unnamed porcine probe-set IDs, we used cross-species relationships between porcine and
human probe-set IDs (U133PlusVsPorcine_Complex sheet) in combination with the human NetAffx
annotation file (Affymetrix HG_U133_Plus_2 Array).
5. Conclusions
We demonstrated no negative effects on tissue-engineered cartilage ECM and chondrocyte
viability for a dose range of CCL25 (0.05–50 nmol/L). These findings are relevant to establish an
in situ repair approach that is based on CCL25 to recruit endogenous repair cells to damaged or
degenerated cartilage sites.
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Abbreviations
ACAN aggrecan
ANK3 ankyrin family member ankyrin 3
BGN biglycan
BSCL2 seipin lipid droplet biogenesis associated
CASQ2 calsequestrin 2
CCL2 C-C motif chemokine ligand 2
CCL25 Thymus-expressed chemokine
CCL3 C-C motif chemokine ligand 3
CCL4 C-C motif chemokine ligand 4
CCL7 C-C motif chemokine ligand 7
CCR9 C-C motif chemokine receptor 9
COL10A1 collagen type X
COL1A1 collagen type I
COL2A1 collagen type II
COMP cartilage oligomeric matrix protein
CSPG4 chondroitin sulfate proteoglycan 4
CXCL12 stromal cell-derived factor 1α
CXCL2 C-X-C motif chemokine 2
DCN decorin
ECM extracellular matrix
EGR1 early growth response protein 1
ESPN espin
ETS1 transcription factors like ETS proto-oncogene 1
FMOD fibromodulin
FOSB FosB proto-oncogene, AP-1 transcription factor subunit




IL-1β interleukin 1 beta
IL8 interleukin-8
IVL involucrin
JAK2 janus kinase 2
JUN jun proto-oncogene, AP-1 transcription factor unit
JUNB jun B proto-oncogene
LEPREL4 leprecan-like 4
LUM lumican
MAPK mitogen-activated protein kinases
MARVELD3 tight-junction component MARVEL domain-containing protein 3
MMP matrix metallopeptidases
MSC mesenchymal stem- or stromal cells
OA osteoarthritis
PI3K-Akt phosphatidylinositol 3-kinase- serine/threonine kinase
POSTN periostin
PTGES prostaglandin E synthase
SLC12A1 solute carrier family 12 member 1
SMPD1 sphingomyelin phosphodiesterase 1
SOD2 superoxide dismutase 2
SOX9 SRY-box 9
TNF-α tumor necrosis factor-α
TTC28 tetratricopeptide repeat domain 28
VCAN versican
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